Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia

British Journal of Haematology

Volumn 112, Issue 2, 2001, Pages 300-307

  Schaich, M ^a   Ritter, M ^b   Illmer, T ^a   Lisske, P ^a   Thiede, C ^a   Schakel U ^a   Mohr, B ^a   Ehninger, G ^a   Neubauer, A ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

AML; lrp; mdr1; mrp1; Ras mutation

Indexed keywords

AMINO ACID; DNA; MULTIDRUG RESISTANCE PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; CASE-CONTROL STUDIES; CYTARABINE; DAUNORUBICIN; FEMALE; GENE EXPRESSION; GENES, MDR; GENES, RAS; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION; PROSPECTIVE STUDIES; PROTEIN-TYROSINE-PHOSPHATASE; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0035127543     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02562.x     Document Type: Article

References (36)

1. Expression analysis of multidrug resistance associated genes in neuroblastomas
2. Expression of mdr1, mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias
3. Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML
4. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
5. GM-CSF incubation prior to treatment with cytarabine or doxorubicin enhances drug activity against AML cells in vitro: A model for leukemia chemotherapy
6. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53
7. The incidence and prognostic significance of mutations in codon 13 of the N-ras gene in acute myeloid leukemia
8. Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors
9. N-ras gene point mutations in Brazilian acute myelogenous leukemia patients correlate with a poor prognosis
10. Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes
11. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: The potential for multiplex signalling
12. The biochemistry of P-glycoprotein-mediated multidrug resistance
13. Antibodies TC-12 ('unique') and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia
14. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs
15. A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples
16. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines
17. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia
18. The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis
19. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study
20. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
21. Function and regulation of ras
22. Signaling pathways mediated by the mitogen-activated protein (MAP) kinase kinase/MAP kinase cascade
23. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia
24. Pathways of Ras function: Connections to the actin cytoskeleton
25. N-ras mutations in adult de novo acute myelogenous leukemia: Prevalence and clinical significance
26. Expression of drug resistance-associated mdr-1, GST pi, and topoisomerase II genes during cell cycle traverse
27. Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia
28. A novel method for direct and fluorescence independent determination of drug efflux out of leukemic blast cells
29. The drug resistance-related protein LRP is the human major vault protein
30. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias
31. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein
32. The Ras signaling pathway and the molecular basis of myeloid leukemogenesis
33. Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance
34. Cell cycle dependent uptake and release of anthracycline by drug-resistant and drug-sensitive human leukaemic K562 cells
35. Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping
36. Expression of lung resistance-related protein (LRP) in non-small cell lung carcinomas of smokers and non-smokers and its predictive value for doxorubicin resistance